Brown, Lisle/Cummings’s Icosavax, Inc. Common Stock ICVX Stock Holding History

Brown, Lisle/Cummings’s Portfolio ICVX Stock Details ICVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-850	Closed	-$13.4K	–	581
2023 Q4	$13.4K	Hold	850	–	–	0.01%	406
2023 Q3	$6.59K	Hold	850	–	–	﹤0.01%	450
2023 Q2	$8.44K	Hold	850	–	–	﹤0.01%	434
2023 Q1	$4.93K	Hold	850	–	–	﹤0.01%	454
2022 Q4	$6.75K	Hold	850	–	–	﹤0.01%	419
2022 Q3	$2.69K	Hold	850	–	–	﹤0.01%	460
2022 Q2	$4.87K	Hold	850	–	–	﹤0.01%	418
2022 Q1	$5.98K	Hold	850	–	–	﹤0.01%	427
2021 Q4	$19.4K	Buy	+850	New	+$22K	0.01%	339

Brown, Lisle/Cummings's ICVX Position: Q1 2024 in Review

Brown, Lisle/Cummings sold out of Icosavax, Inc. Common Stock (ICVX) in Q1 2024, closing a stake of 850 shares — an estimated $13.4K sold.

Brown, Lisle/Cummings first reported a position in ICVX in Q4 2021 and held it in 9 quarters. The position peaked at $19.4K in Q4 2021. 0 funds tracked by Wall St. Rank hold ICVX as of Q1 2024.

Brown, Lisle/Cummings reported no remaining Icosavax, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Brown, Lisle/Cummings sold 850 Icosavax, Inc. Common Stock shares in Q1 2024, an estimated $13.4K.
Brown, Lisle/Cummings first reported a position in Icosavax, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Brown, Lisle/Cummings's Icosavax, Inc. Common Stock position peaked at $19.4K in Q4 2021.
0 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q1 2024.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2024, filed 1 Jul 2024.